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ABSTRACT
Objective: The objective of this research was to evaluate prescribing pattern of fixed dose combinations (FDCs) of antihypertensives and antidiabetic 
agents among patients of private hospitals.
Methods: An observational study was carried out in the outpatient department of two hospitals. Data of patients being diagnosed with the symptoms 
of hypertension and diabetes were enrolled which mainly included information related to prescribe FDCs, i.e., antihypertensives and antidiabetics, 
respectively. Descriptive analysis of collected information was done which involved representation of demographical data, number of comorbidities, 
number of FDCs prescribed, and type of FDCs consequently.
Results: Combination drug therapy was prescribed in maximum patients, which was enumerated as 93% among hypertensive patients and about 91% 
in diabetics. Average age of patients suffering more from hypertension was 64.5±18 years and that in case of diabetes sufferers was 54.5±18 years. 
The most frequent combination prescribed in hypertensive patients was of angiotensin receptor blocker (ARB) and calcium channel blocker (CCB) 
which were about 53%, and in diabetic patients, it was of biguanides and sulfonylureas about 63%. Comorbidity too was notified, and its estimation 
was 61% in hypertensive patients and 72% in diabetic patients, respectively.
Conclusion: The study here demonstrates that the most often prescribed antihypertensive combination is of ARB and CCB, and subsequently for 
diabetes, the oral hypoglycemic combination is of biguanides and sulfonylureas. Most of FDCs contained medications of these two classes. Positive 
results were also observed in levels of blood pressure and glucose within the normal range.
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INTRODUCTION
Nowadays, hypertension and diabetes are considered to be in the 
category of most common diseases among individuals. Specificity of 
patient’s prescription depends on individuals age, gender, and presence 
of comorbid condition if any. Furthermore, the follow-up guidelines, 
i.e., by the World Health Organization (WHO) and the Joint National 
Committee (JNC) are necessary as also the follow up guidelines i.e. by 
World Health Organization and Joint National Committee are necessary. 
These guidelines are indicative as standard one and patient’s glucose and 
BP levels should be determined in its comparative terms. Dependency of 
pharmacological treatment is also on age, gender, and body mass index. 
In most of the cases, more than one drug is required to control BP or 
glucose level. The categorization of the drugs as to be given as single or 
in combination is dependent on JNC and other such regulations. In initial 
treatment terms, single therapy is being employed which later is being 
followed with a combined therapy on basis of patient’s health condition. In 
case of hypertensive patients, therapy management done by the JNC is as 
per stages [1]: Stage 1: BP (>140/90 mmhg) first recommended calcium 
channel blocker (CCB) and if needed add angiotensin-converting enzyme 
(ACE)/angiotensin receptor blocker (ARB) and second recommended 
is CCB+thiazide and addition of beta blockers (BBs) is done to it. Stage 
2: BP (>160/100 mmhg), started with two drugs which are CCB or 
thiazide+ACE or ARB and ended with three drugs combined which are 
CCB+thiazide+ACE/ARB. For diabetic patients, pharmacological therapy 
is in terms of insulin usage as a prime preference in diabetes mellitus 
(DM)-1 patients and oral hypoglycemic agents’ usage in DM-2 sufferers. 
Guidelines of WHO are utilized as prescribing indicators on the basis of 
which antidiabetic drugs are to be prescribed by Ramachandran et al. [2] 
and Shahir et al. [3]. Drug management is done as follows [3,4]: If normal 
glucose level is not achieved by lifestyle modification, then metformin is 
given as initial treatment drug. If single oral hypoglycemic agent does not 
seem useful, then the second agent is added along with the first one, and 
combinative treatment is advised. These fixed dose combinations (FDCs) 
are defined to be as manufactured medications containing mixture 
of two or more drugs with the aim of targeting required physiological 
system at cellular level and providing essential therapeutic outcome by 
blocking other counter regulatory responses even at their low doses 
[5,6]. Substances/agents used in these FDCs are selected in a manner, 
where both possess opposite side effects and must act as neutralizing 
one consequently [5,6]. Combination therapy preferred must be in 
consideration of convenience and tolerability of the patient with least 
adverse effects. As per the JNC, classification of antihypertensives is 
done as follows: CCBs, diuretics, ARBs, and ACE inhibitors (ACEI) [5,6]. 
Similarly, as per the WHO, classification of antidiabetics is done as follows: 
Biguanides, sulfonylureas, thiazolidinedione, and dipeptidyl peptidase-4 
inhibitors. Advantages of these combined drug therapies are rationalized 
administration, better acceptance, decreased troublesome in capsule 
consumption, and reduction in the cost compared to individual medicines 
[5,6], on other sides, its disadvantages are a reduction in dose versatility 
and elevation in dose-dependent reactions [5,6]. Evaluation of drug 
usage can thus be considered as a helping tool in recognizing condition of 
disease, medication prescribing process, and drug usage process which 
eventually confers as a rational drug treatment [7]. Hence, the main aim 
of this study was to narrate prescription pattern among hypertensive and 
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diabetic patients in the outpatient department of two hospitals to explain 
the FDC treatment as a better method of drug management.
METHODS
Context
An observational and descriptive study was conducted in the outpatient 
department of two hospitals: Mahagujarat Multispecialty Hospital, 
Nadiad, India and SARATHI Institute of Diabetes Sciences, Anand, India. 
The time period of study as whole was of 6 months.
Data collection
The study got the approval from the Human Resource Ethics Committee, 
Department of Pharmacology, Pramukhswami Medical College, 
Karamsad, India, for its operation. Data were collected during the period 
of 2½ to 3 months, i.e., from August 2016 to October 2016. Evaluation 
and analysis of the data were done in remaining 3 months. A total of 
about 200 patients data, i.e., (hypertension:diabetes) = (100:100) 
with age greater than 18 years were reviewed. Their demographic 
information such as gender, age, and BP were noted from patient’s 
OPD sheet. Along with details, information on prescribed medications, 
and especially, of FDCs was notified on the basis of their type, content 
names, and dosage. Information about patient’s particular comorbid 
condition was also being collected.
Statistical evaluation
After data collection process, separation of data was done in terms of 
specific therapy kind, i.e., two/three drug therapy, type of FDC, and dose 
and patient’s consumption proportion, respectively. Statistical analysis 
was performed through usage of Microsoft Excel. Appropriate results 
obtained here are depicted in tabular form. Concern regarding patient’s 
privacy and confidentiality was maintained during the study and will 
remain conserved even during the publication.
RESULTS
Here, the demographic details entered were indicative of male and 
female proportion suffering from hypertension and diabetes. The ratio 
for the same was 48:52 for hypertensives and 60:40 for diabetics. 
The proportion of comorbidity present in hypertensive patients was 
61%, and in diabetic patients, it was 72%. In dependence of patient’s 
health condition, he/she is being started with particular two-/three-
drug therapy. In case of hypertensive patients, the utilization of two-
drug therapy is about 97%with no three drug treatment. Whereas, 
in diabetics, two-drug therapy counts 76% and three-drug therapy 
counts 15% which in total contribute 91% of combined drug therapy. 
The most often prescribed combination observed in hypertensives 
is of CCBs and ARBs contributing 53%. Similarly, for diabetics, the 
most common prescribed two-drug combination was of biguanides 
and sulfonylureas accounting 63% and three-drug therapy was of 
metformin, sulfonylureas, and glitazones combination, contributing 
11%, respectively.
Table 1 shows age- and gender-wise distribution of the patients 
suffering from hypertension and diabetes. It shows that the numbers of 
hypertensive patients are seen more in the elderly group. Whereas, age 
group between 51 and 60 years suffered more from diabetes compared 
to other age groups. There is not much difference in gender distribution 
for both morbidities.
Table 2 shows comorbid conditions of the patients of different age 
groups. It shows most of the patients suffered from single morbidity. 
Patients having hypertension with other comorbidities are very 
less, i.e., one patient in the age group of 51-60. Patients of diabetes 
with maximum comorbidities are seen in the elderly patients, 
i.e., 3 comorbidities.
Table 3 shows age-wise distribution of patients on basis of number 
of antihypertensive and antidiabetic drugs per prescription. In 
hypertensive patients, two drug treatments are found to be maximum in 
elderly group and are seen lowest in 31-40 years age group. In diabetic 
patients, two-drug therapies are found maximum in 51-60 years age 
group and lowest in 18-30 years. More than three antidiabetic drugs are 
seen prescribed in the age group of 51-60 years (Table 4).
DISCUSSION
A prescription-based survey is significant in terms of measuring/
evaluating the ethos of doctors, i.e., physicians and also the customs 
of chemists/druggists in case of distributing medications [8] so as 
to achieve rationality in maintaining proper medical protection [9]. 
The other important matters which are to be considered are looking 
after the WHO as well as the JNC regulations to maintain sanity of 
medications as per the essential drugs list [10].
The study carried out here disclosed that the hypertension is seen to 
be more prevailing in females (52%) compared to males (48%) which 
is identical to the project conducted by Bajaj et al. (2012) in Northern 
Table 1: Demographic detail
Age (years) Hypertensives, n (%) Diabetics, n (%)
Male Female Total Male Female Total
18-30 0 0 0 4 (4) 6 (6) 10 (10)
31-40 6 (6) 3 (3) 9 (9) 8 (8) 0 8 (8)
41-50 6 (6) 4 (4) 10 (10) 11 (11) 6 (6) 17 (17)
51-60 10 (10) 17 (17) 27 (27) 20 (20) 18 (18) 38 (38)
>60 26 (26) 28 (28) 54 (54) 17 (17) 10 (10) 27 (27)
Total 48 (48) 52 (52) 100 (100) 60 (60) 40 (40) 100 (100)
Table 2: Co-morbid conditions
Age group (years) Hypertensives Diabetics
Number of comorbidities, n (%)
1 2 3 4 Total 1 2 3 4 Total
18-30 0 0 0 0 0 0 0 0 0 0
31-40 1 (1) 2 (2) 0 0 3 (3) 1 (1) 0 2 (2) 0 3 (3)
41-50 7 (7) 0 0 0 7 (7) 5 (5) 3 (3) 2 (2) 0 10 (10)
51-60 8 (8) 6 (6) 2 (2) 1 (1) 17 (17) 21 (21) 8 (8) 6 (6) 1 (1) 36 (36)
>60 23 (23) 8 (8) 3 (3) 0 34 (34) 8 (8) 9 (9) 3 (3) 3 (3) 23 (23)
Total 39 (39) 16 (16) 5 (5) 1 (1) 61 (61) 35 (35) 20 (20) 13 (13) 4 (4) 72 (72)
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India as that showed data of females as 58% and males accounting 
42% [11], whereas the study ran by Jhaj et al. was exactly opposite, 
i.e., male sufferers were more than females [12], and also hypertension 
cases in these studies were seen to be more prevailing in elderly group 
patients which were similar to a prospective study been carried out at 
Annamalai Nagar, India [13].
Combinative therapy given in case of, especially, hypertensive patients 
is helpful in reducing the death rates which occurs due to cardiovascular 
disorders as a chronic comorbid disease with hypertension [14]. 
As per the JNC-8 report after evaluation, it was revealed that in case 
of the usage of ARB in management of HTN as a single therapy or in 
combination therapy with other drugs shows maximum compliance as 
per its rules and regulations (JNC-8).
Furthermore, the diuretics are found to be used in less amount in case of 
combination therapy, and here in these experiments, the maximum usage 
found of combination therapy is of ARBs and CCBs, i.e., most frequently 
used one which is about 53% then followed by ARBs and thiazide diuretics 
(TDs) showing 18% of the use. Diuretics if used then it is seen more in 
single-drug therapy and specifically during initiation of hypertension in 
patient. The least used combination is of BBs and TDs counting only 1%. 
The peculiarity of combination is also dependent on extent of the disease 
also the comorbidity associated with it. For example, combination of BBs 
and CCBs is used more in condition of arterial hypertension [15]. Usage 
of diuretics is in such a manner that it is mostly used at low doses even in 
combination treatment because of it contradictory effects on processes 
such as glucose balance and also the fat profile [16].
As per the previous studies, the requisite to be considered important is 
that the drugs/antihypertensives which are used that must possess a 
coactive/collaborative action even at lower doses and that too with no 
side effects [17].
DM is chronic disease which comprehends several other metabolic 
deformities out of that the main one is hyperglycemia [18].
This type of studies on prescription monitoring and estimation can prove 
as helpful in promoting well-advised drug therapy because of which the 
assumed level of glucose can be attained in patients and possibilities of 
death as well as morbidities can be eventually reduced [2].
From this study, we observed that the disease is seen to be more 
existed among individuals of age group 50-60 years, i.e., about 38%. 
Table 3: Prescribing pattern
Age group (years) Hypertensives, n (%) Diabetics, n (%)
Two-drug therapy Three-drug therapy Total Two-drug therapy Three-drug therapy Total
18-30 0 0 0 3 (3) 0 3 (3)
31-40 8 (8) 0 8 (8) 5 (5) 2 (2) 7 (7)
41-50 18 (18) 0 18 (18) 17 (17) 3 (3) 20 (20)
51-60 25 (25) 0 25 (25) 29 (29) 7 (7) 36 (36)
>60 46 (46) 0 46 (46) 22 (22) 3 (3) 25 (25)
Total 97 (97) 0 97 (97) 76 (76) 15 (15) 91 (91)
Based on number of drugs in single FDCs. FDCs: Fixed dose combinations
Age group (years) Hypertensives (two-drug therapy), n (%)
ARB+CCB BB+CCB BB+ARB ARB+TD TD+CA KD+LD Total
18-30 0 0 0 0 0 0 0
31-40 4 (4) 3 (3) 0 1 (1) 0 0 8 (8)
41-50 4 (4) 2 (2) 0 2 (2) 1 (1) 1 (1) 10 (10)
51-60 7 (7) 4 (4) 2 (2) 6 (6) 0 3 (3) 22 (22)
>60 38 (38) 8 (8) 0 9 (9) 0 2 (2) 57 (57)
Total 53 (53) 17 (17) 2 (2) 18 (18) 1 (1) 6 (6) 97 (97)
Diabetics (two-drug therapy), n (%)
B+SU B+G B+AGI B+DPP B+CYNOCOBAL SU+G Total
18-30 3 (3) 0 0 0 0 0 3 (3)
31-40 3 (3) 1 (1) 0 0 0 1 (1) 5 (5)
41-50 12 (12) 0 0 1 (1) 1 (1) 0 14 (14)
51-60 28 (28) 2 (2) 1 (1) 1 (1) 2 (2) 0 34 (34)
>60 17 (17) 0 1 (1) 1 (1) 1 (1) 0 20 (20)
Total 63 (63) 3 (3) 2 (2) 3 (3) 4 (4) 1 (1) 76 (76)
Three-drug therapy, n (%)
B+SU+G B+SU+AGI B+AGI+G Total
18-30 0 0 0 0
31-40 2 (2) 0 0 2 (2)
41-50 1 (1) 1 (1) 1 (1) 3 (3)
51-60 6 (6) 1 (1) 0 7 (7)
>60 2 (2) 0 1 (1) 3 (3)
Total 11 (11) 2 (2) 2 (2) 15 (15)
Summed 91 (91)
ARB: Angiotensin receptor blocker, CCB: Calcium channel blocker, TD: Thiazide diuretics, CA: Centrally acting agents, KD: Potassium-sparing diuretics, LD: Loop 
diuretics, B: Biguanides, SU: Sulfonylureas, G: Glitazones, Alpha-glucosidase inhibitors, DPP: Dipeptidyl peptidase inhibitor, CYANOCOBAL: Cyanocobalamin, FDCs: Fixed 
dose combinations
Table 4: Frequencies of specifically prescribed FDCs
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This detection is found similar to a research work been conducted 
by Upadhyay et al. [19] as conventionally too it was observed among 
people of age >50 years. It is observed that males are suffering 
more than females which is opposite to the study been conducted in 
New York [20].
Around 91% of patients are receiving combination therapy such 
as DM is a slowly spreading chronic metabolic disease that cannot 
be controlled by single-drug therapy, which was similar to a study 
conducted once where the ratio of patients receiving combination 
therapy was more than 71.5%. The most often prescribed ones contain 
biguanides+sulfonylureas accounting 63% which was similar to a study 
conducted in the UK portrayed that this mixture showed up better result 
in terms of level of HbA1C [21]. Then, this was followed with combination 
of biguanides+thiazolidinedione which counted 3%, and the least 
prescribed combination was of sulfonylureas+thiazolidinedione, i.e., 1%. 
In three-drug therapy consideration, the frequently prescribed one was 
biguanides+sulfonylureas+thiazolidinedione combination which was 
11%. This report matched with the one which was once conducted 
on ambulatory patients in Lahore, Pakistan [22], and also the specific 
combination of metformin+glibenclamide+pioglitazone contributed 
11% among patients of these studies which was exactly opposite to a 
study implemented on non-hospitalized patients of Iran [7].
In all the prescribed medication, it has been observed that along 
with this present study too biguanides are recommended in higher 
proportion, whether this is in terms of single therapy or combinative 
therapy, this was applicable for both the treatments [22].
In addition, issuing comorbid conditions and multiple drug therapy, 
chances of drug interactions, unacceptability, and side effects will be 
seen aggravating more. For this proper and complete drug, optimization 
is mandatory by the doctors along with making them aware with the 
risks. For example, patient with hypertension and diabetes if is given 
with combinative therapy of BB+ACEI for hypertension specifically, 
then it will indirectly reduce action of oral hypoglycemic agents either 
or will result into hypoglycemia in the patient. This is indicative that 
appropriate dose adjustment is must.
Lifestyle changes, diet monitoring, regular exercises, and weight loss 
can be considered as important ways in controlling DM and several 
other severe diseases [23].
Eventually, prescribing practices must be developed on the basis of 
scientific proofs and considering drug management guidelines and 
regulations as standard in terms of adjusting proper dosage regimen 
depending on condition of the particular patient [22].
CONCLUSION
The prescribing methodology of FDCs is found to be more in common 
here than single drug therapy. The most often prescribed FDC for 
hypertension found is of ARBs and CCBs group kind. Similarly, for 
diabetes, the frequently prescribed combination was of biguanides and 
sulfonylureas. Maximum medications belonged to these two classes. 
Positive results in the end were seen in case of BP and glucose levels 
because of these prescribed medications. More awareness is still 
required among patients regarding the importance of regular uptake 
of medications.
ACKNOWLEDGMENT
The authors would like to thank Mr. Anup Desai and Dr. Vikram Valand 
of Maha Gujarat Multispecialty Hospital, Nadiad and also Dr. Chintan 
Vyas of SARTHI Institute of Diabetes Sciences, Anand, for permitting us 
to perform our desired work and also for their support and cooperation.
REFERENCES
1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb 
C, Handler J, et al. Evidence-based guideline for the management of 
high blood pressure in adults report from the panel members appointed 
to the eighth joint national committee (JNC 8). JAMA. Doi: 10.1001/
jama.2013.284427.
2. Ramachandran G, Rohith V, Topno I. Evaluation of prescribing 
pattern of anti-diabetic drugs using WHO prescribing indicators in a 
tertiary care hospital in Pondicherry: A cross-sectional study. Int J Clin 
Pharmacol Thyer 2015;4(5):76-80.
3. Shahir AQ, Kauser S, Dharmendra G, Ahmad AN. Prescribing 
patterns of anti-diabetic medications in tertiary care teaching hospital, 
Bareilly, UP, India. J Pharm Sci Innov 2013;2(1):41-6.
4. Sridevi SA, Ganesh M. Study on the Prescription Pattern of Oral 
Hypoglycemic Agents in Type 2 Diabetes Mellitus in the Outpatient 
Department of a Tertiary Care Hospital in Chennai. Vol. 6. March; 
2016.
5. Murthy S, Jambulingappa KL, Gokul, Ramakrishna S, Acharya A, 
Adake P. Prescribing patterns of anti-hypertensive combinations 
in a tertiary care setting, Karnataka, India. Drug Invent Today 
2011;3(11):265-9.
6. Kale A, Maniyar YA. Prescribing patterns of antihypertensive drugs in 
a tertiary care hospital, Karnataka, India. Acd J Pharm 2013;2(5):416-8.
7. Moradi M, Mousavi S. Drug use evaluation of diabetes mellitus in non-
hospitalized patients. Int J Pharm Pharm Sci 2016;8(8):337-41.
Hypertensives (ARBS+CCBS), n (%)
Age group (years) T+A (40/5) mg T+C (40/10) mg O+A (40/10) mg Total
18-30 0 0 0 0
31-40 4 (4) 0 0 4 (4)
41-50 4 (4) 0 0 4 (4)
51-60 8 (8) 1 (1) 0 9 (9)
>60 23 (23) 12 (12) 1 (1) 36 (36)
Total 39 (39) 13 (13) 1 (1) 53 (53)














18-30 0 1 (1) 2 (2) 0 0 0 3 (3)
31-40 0 2 (2) 1 (1) 0 0 2 (2) 5 (5)
41-50 5 (5) 0 6 (6) 0 1 (1) 1 (1) 13 (13)
51-60 14 (14) 8 (8) 5 (5) 0 0 6 (6) 33 (33)
>60 6 (6) 3 (3) 8 (8) 1 (1) 0 2 (2) 20 (20)
Total 25 (25) 14 (14) 22 (22) 1 (1) 1 (1) 11 (11) 74 (74)
Based on dose of each drug. T: Telmisartan, A: Amlodipine, C: Clinidipine, O: Olmesartan, M: Metformin, Glim: Glimepiride, Glyc: Glyclazide, Glipi: Glipizide, 
Glyb: Glyburide, Gliben: Glibenclamide, Piog: Pioglitazone, ARB: Angiotensin receptor blocker, CCB: Calcium channel blocker
Table 5: Prescribing pattern of frequently prescribed FDCs
168
Asian J Pharm Clin Res, Vol 10, Issue 9, 2017, 164-168
 Vyas et al. 
8. Yuen YH, Chang S, Chong CK, Lee SC, Critchlev JA, Chan JC. Drug 
utilization in a hospital general medical outpatient clinic with particular 
reference to antihypertensive and ant diabetic drugs. J Clin Pharm Ther 
1998;23:287-94.
9. Suheela SH, Narendranth S, Somashekhar HS, Reshma SR, Keerthi SJ, 
Ramachandra K. Prescriptive pattern of antihypertensive in a tertiary 
care hospital using DU-90%. Int J Pharm Res Dev 2011;4(1):107-13.
10. Sikidar P, Chakravarty P, Purkayastha A, Tigga R. A Study on 
prescribing pattern of antihypertensive in adult patients attending in 
a tertiary care hospital of Assam, India.  Int J Basic Clin Pharmacol 
2016;5(3):975-8.
11. Bajaj JK, Sood M, Singh SJ, Jerath P. Prescription patterns of 
antihypertensive drugs and adherence to JNC VII guidelines in a tertiary 
care hospital in North India. Int J Med Clin Res 2012;3(2):118-20.
12. Jhaj R, Goel NK, Gautam CS, Hota D, Sangeeta B, Sood A, et al. 
Prescribing patterns and cost of antihypertensive drugs in an internal 
medicine clinic. Indian Heart J 2001;53(3):323-7.
13. Nachiya RA, Parimalakrishnan S, Rao MR. Cost analysis of 
antihypertensive agents in rural population: A prospective study. Int J 
Pharm Pharm Sci 2016;8(3):225-30.
14. Mancia G, Grassi G. Antihypertensive treatment: Past, present and 
future. J Hypertens Suppl 1998;16(1):S1-7.
15. Carré A. Pharmacologic importance of the combination atenolol/
nifedipine in hypertensive patients. Drugs 1998;56 Suppl 2:23-30.
16. Prisant LM, Beall SP, Nicholads GE, Feldman EB, Carr AA, 
Feldman DS, et al. Biochemical, endocrine, and mineral effects of 
indapamide in black women. J Clin Pharmacol 1990;30:121-6.
17. Tiwari H, Kumar A, Kulkarni SK. Prescription monitoring of anti-
hypertensive drug utilisation at the Panjab university health centre in 
India. Singapore Med J 2004;45(3):117-20.
18. Rajan SK, Sivakumar R, Arunaprakash J. The study of plasma 
glycosylated hemoglobin and fibrinogen levels in patients with Type 2 
diabetes mellitus and its complication. Asian J Diabetol 2005;7:9-12.
19. Upadhyay DK, Palaian S, Shanker PR, Mishra P, Sah AK. Prescribing 
pattern in diabetic outpatients in a tertiary care teaching hospital in 
Nepal. J Clin Diagn Res 2007;3:248-55.
20. Flier JS, Maratos-Flier E. Obesity. In: Kasper DL, Braunwald E, 
Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s 
Principles of Internal Medicine. 16th ed., Vol. 1. New York: Medical 
Publishing Division, McGraw-Hill; 2005. p. 422-9.
21. UKPDS 28: A randomized trial of efficacy of early addition of 
metformin in sulfonylurea-treated Type 2 diabetes. U.K. Prospective 
diabetes study group. Diabetes Care 1998;21(1):87-92.
22. Bukhsh A, Liaqat I, Javaid S, Bashir M, Khan B, Yaseen H, et al. 
Prescription analysis of ambulatory patients of diabetes mellitus in 
Lahore Pakistan. Adv Pharm Ethnopharmacol Med 2014;2(2):21-5.
23. Laakso M, Letho S. Epidemiology of macrovascular disease in diabetes. 
Diabet Rev 1997;5:294-315.
